IMMUTEP LIMITED
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
Company positioning and business
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. [3]
Prima currently has three main products in its pipeline, all acquired with Immutep: [3]
Eftilagimod alpha, (lab name: IMP321) which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer. [3]
Background text: Wikipedia contributors, Immutep. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Financial year, securities and disclosures
ASX security code: IMM. The exchange profile links to announcements and security information. [1]
History and key events
Founding / inception date recorded in Wikidata. [2]
Financial results and regulatory disclosures
No individual financial documents have been indexed yet. Open the source to consult company disclosures. [1]
Source-verified relationships
Companies in the same industry
Comparison candidates share the ASX industry group classification Pharmaceuticals, Biotechnology & Life Sciences. This does not imply ownership, partnership or trading relationships.
Related entities and concepts
Frequently asked questions
When was IMMUTEP LIMITED founded?
Founded: 2001. The linked source provides the background record. [2]
Where is the headquarters of IMMUTEP LIMITED?
Headquarters location: Sydney. The linked source provides the background record. [2]
Which business sectors are recorded for IMMUTEP LIMITED?
Business sectors: pharmaceutical industry. The linked source provides the background record. [2]
IMMUTEP LIMITED relationship map
Select a node to inspect its relationship and source.
1 verified direct relationships. Industry peers are not relationship edges.
Sources and review dates
- Company identity and profile data ↗
- Wikidata — company background record (CC0) ↗
- Wikipedia contributors — Immutep (CC BY-SA 4.0) ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.